Non-clinical safety evaluation of vaccines accelerating clinical development part II
Manufacturing Chemist: Sebastian Joseph discusses regulatory expectations for the non-clinical development of vaccines
Posted:
ReadSupporting M&As in the pharmaceutical/biopharmaceutical industry
Manufacturing Chemist: At PharmaLex, we believe we have a unique understanding of the cultural challenges experienced during M&As. Having merged ourselves in 2017 into PharmaLex, we have insight in how to overcome the challenges of maintaining agility while benefiting from working in a bigger corporate environment, having economies of scale with an increased resource pool.
Posted:
ReadTogether Beyond COVID-19
PharmaLex.perts Jürgen Hönig and Lisa Pascoe discuss the challenges COVID-19 has placed on the pharma industry – from R&D to clinical trials and manufacturing to drug safety – and how companies like PharmaLex are working together with the industry to ensure regulatory compliance.
Posted:
ReadIs there a way of safeguarding the supply of medicines in the case of a ‘no deal’ Brexit?
Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit
Posted:
ReadBrexit Uncertainty - impact on medicines supply
PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU
Posted:
ReadThe Pink Sheet - Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
PharmaLex’s Bruno Boulanger discusses the impact big data will have on how the pharmaceutical industry gathers and delivers data in the future. *subscription required*
Posted:
ReadThe 5 things you want to know about Artificial Intelligence
PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence
Posted:
Read